Lorenz Mayr

Dr. Mayr’s experience in drug discovery and development, and specifically his expertise in functional genetic screening in target identification, will help drive the expansion of PhoreMost’s next-generation SITESEEKER® target discovery platform and guide the development of the Company’s drug discovery programme.

Dr. Mayr is Chief Technology Officer at GE Healthcare Life Sciences, where he is responsible for R&D strategy and innovation across all life sciences business areas. He has extensive global experience in pharmaceutical R&D, including holding positions as Vice President & Global Head at AstraZeneca and Executive Director at Novartis Pharmaceuticals and Bayer Pharmaceuticals. Dr. Mayr gained his Ph.D. at the University of Bayreuth in Biochemistry and Biophysics, subsequently completing his PostDoc at the M.I.T/Whitehead Institute in Cambridge, US.